Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
BMC Pediatrics
Published in: BMC Pediatrics 1/2024

Open Access 01-12-2024 | Kawasaki Disease | Research

The effect of vitamin D status on the occurrence of Kawasaki Disease: a meta-analysis

Authors: Haixiang Zhang, Fuyong Jiao, Jiaojiao Wang, Cuixiang Xu, Kejin Zhang

Published in: BMC Pediatrics | Issue 1/2024

Login to get access

Abstract

Aim

The relationship between vitamin D status and Kawasaki Disease (KD), as well as coronary artery lesion (CAL), has yet to be established.

Methods

A meta-analysis was conducted to assess the correlation between vitamin D status and KD, as well as the impact of vitamin D status on the progression of KD into CAL.

Results

The meta-analysis revealed a consistent and significant association between serum 25(OH)D level and the occurrence KD (studies N = 22; z = -3.51, P < 0.001). Patients with KD had markedly lower levels of vitamin D than healthy controls (SMD: -1.30 ng/mL, 95%CI: -2.05 to -0.55 ng/mL).

Conclusion

The study provided evidence supporting a significant association between lower serum vitamin D levels and the occurrence of KD, particularly within the Chinese population. However, the findings did not suggest a direct impact of vitamin D on the development of CAL in KD patients.
Appendix
Available only for authorised users
Literature
1.
Kawasaki T. Acute febrile mucocutaneous syndrome with lymphoid involvement with specific desquamation of the fingers and toes in children. Arerugi. 1967;16(3):178–222.PubMed
2.
Holman RC, et al. Kawasaki syndrome hospitalizations in the United States, 1997 and 2000. Pediatrics. 2003;112(3 Pt 1):495–501.PubMedCrossRef
3.
Huang GY. Challenges in the diagnosis and treatment of Kawasaki disease. Zhonghua Er Ke Za Zhi. 2022;60(1):3–5.PubMed
4.
Correction to: Diagnosis, Treatment, and Long-Term Management of Kawasaki Disease: A Scientific Statement for Health Professionals From the American Heart Association. Circulation, 2019. 140(5):e181–e184.
5.
Baker AL, Newburger JW. Cardiology patient pages Kawasaki disease. Circulation. 2008;118(7):e110–2.PubMedCrossRef
6.
Kato H, et al. Long-term consequences of Kawasaki disease. A 10- to 21-year follow-up study of 594 patients. Circulation. 1996;94(6):1379–85.
7.
Kim DS. Kawasaki disease. Yonsei Med J. 2006;47(6):759–72.
8.
L Bishop E, et al. Vitamin D and Immune regulation: antibacterial, antiviral, anti-inflammatory. JBMR Plus. 2021;5(1):e10405.PubMedCrossRef
9.
10.
Saenger AK, et al. Quantification of serum 25-hydroxyvitamin D(2) and D(3) using HPLC-tandem mass spectrometry and examination of reference intervals for diagnosis of vitamin D deficiency. Am J Clin Pathol. 2006;125(6):914–20.PubMedCrossRef
11.
Xu B, et al. Vitamin D status in children with short stature: accurate determination of serum vitamin D components using high-performance liquid chromatography-tandem mass spectrometry. Front Endocrinol (Lausanne). 2021;12:707283.PubMedCrossRef
12.
Holick MF. Vitamin D status: measurement, interpretation, and clinical application. Ann Epidemiol. 2009;19(2):73–8.PubMedCrossRef
13.
Falcini F, et al. Severe vitamin D deficiency in patients with Kawasaki disease: its possible role in the risk to develop coronary artery damage. Ann Rheum Dis. 2015;74:843–843.CrossRef
14.
Huang J-H, et al. Value of serum 25-Hydroxyvitamin D levels in the prediction of intravenous immunoglobulin resistance in patients with complete Kawasaki disease. J Modern Lab Med. 2022;37(1):5.
15.
Jiang H-F, Gao J, Han W-N. Study on serum vitamin D level and vitamin D receptor Fok I gene polymorphism in children with Kawasaki disease. Mat Child Health Care China. 2020;35(3):4.
16.
Okazaki N, et al. The impact of vitamin D on the onset and progress of Kawasaki disease. Pediatr Int. 2022;64(1):e15191.PubMedCrossRef
17.
Ren J, Wu X. The value of serum 25(OH)D3, NT-proBNP and IL-6 in early diagnosis of Kawasaki diaease in children. Chinese J Woman Child Health. 2021;32(5):4.
18.
Stagi S, et al. Severe vitamin D deficiency in patients with Kawasaki disease: a potential role in the risk to develop heart vascular abnormalities? Clin Rheumatol. 2016;35(7):1865–72.PubMedCrossRef
19.
Wen H-Y, Jing X-A. Clinical significance of changes of vitamin A, 25-hydroxyvitamin D in children with Kawasaki disease. Home Medicine. 2018;7:1.
20.
Zhang X-Y, et al. Changes and clinical significance of serum 25-hydroxyvitamin D levels in children with Kawasaki disease. China Modern Med. 2019;26(5):3.
21.
Zhang Y, et al. The significance of changes in endogenous hydrogen sulfide and 25-hydroxyvitamin D3 levels in children with Kawasaki disease. J Imag Res Med. 2018;2(15):3.
22.
Zhang YD, et al. Changes in 25-hydroxyvitamin D3 level and its significance in children with Kawasaki disease. Zhongguo Dang Dai Er Ke Za Zhi. 2016;18(3):211–4.PubMed
23.
Zhou Z, et al. 1α, 25-dihydroxyvitamin D3 inhibits THP-1 cell inflammatory factor expression induced by Kawasaki disease serum through TLR4 signal pathway. Chinese J Pathophysiol. 2022;38(1):9.
24.
Zhu J, Peng H. Serum 25 - (OH) D_ (3) Expression of NT-proBNP and IL-6 in children with Kawasaki disease and their correlation analysis. China Med Eng. 2021;29(12):109–11.
25.
An X, et al. Significance of serum 25-hydroxyvitamin D(3) and interleukin-6 levels in immunoglobulin treatment of Kawasaki disease in children. Exp Ther Med. 2016;12(3):1476–80.PubMedPubMedCentralCrossRef
26.
Chen X-H, et al. Serum 25 hydroxyvitamin D3 in predicting coronary arterial lesions of Kawasaki disease. Chinese J Woman Child Health Res. 2019;30(5):4.
27.
Chen YL, Wang JL, Li WQ. Prediction of the risk of coronary arterial lesions in Kawasaki disease by serum 25-hydroxyvitamin D3. Eur J Pediatr. 2014;173(11):1467–71.PubMedPubMedCentralCrossRef
28.
Que XJ, et al. Predictive value of serum PA, NT-proBNP and 25-(OH)D3 levels on the risk of coronary artery disease in children with Kawasaki disease. J North Sichuan Med College. 2022;37(6):4.
29.
Wang Y-L, et al. Changes in serum 25 - (OH) D3 and T cell subsets in children with Kawasaki disease. Chinese J Woman Child Health. 2015;26(2):2.
30.
Moher D, et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann Internal Med. 2009;151(4):264-69.
31.
Ayusawa M, et al. Revision of diagnostic guidelines for Kawasaki disease (the 5th revised edition). Pediatr Int. 2005;47(2):232–4.PubMedCrossRef
32.
Editorial Committee of Chinese Journal of Pediatrics C.G.o.C.P.S, Immunology Group of Chinese Peediatric Society. Summary of Kawasaki Disease Symposium. Chinese Journal of Pediatrics. 2007;45(11):5.
33.
Wells GA, D O’Connell SB, Peterson J, Welch V, Losos M, Tugwell P. The Newcastle-Ottawa Scale (NOS) for Assessing the Quality of Non-Randomised Studies in Meta-Analyses. in Symposium on Systematic Reviews: Beyond the Basics. 2014.
34.
35.
Viechtbauer W. Conducting meta-analyses in R with the metafor package. J Stat Softw. 2010;36(3):1–48.CrossRef
36.
Cuijpers P. Meta-analyses in mental health research. A practical guide. Amsterdam, the Netherlands: Pim Cuijpers Uitgeverij. 2016.
37.
Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med. 2002;21(11):1539–58.PubMedCrossRef
38.
Harrer M, et al. Doing Meta-Analysis in R: A Hand-on Guide. 2019.
39.
Dong Y, et al. Effects of vitamin D(3) and marine omega-3 fatty acids supplementation on biomarkers of systemic inflammation: 4-year findings from the VITAL randomized trial. Nutrients. 2022;14(24):5307.PubMedPubMedCentralCrossRef
40.
Ribeiro VR, et al. Vitamin D modulates the transcription factors of T cell subsets to anti-inflammatory and regulatory profiles in preeclampsia. Int Immunopharmacol. 2021;101(Pt B):108366.PubMedCrossRef
41.
Qi XL, et al. 1,25-Dihydroxyvitamin D3 regulates T lymphocyte proliferation through activation of P53 and inhibition of ERK1/2 signaling pathway in children with Kawasaki disease. Eur Rev Med Pharmacol Sci. 2017;21(16):3714–22.PubMed
42.
Shahbaznejad L, et al. Epidemiological data of national Kawasaki disease registry in Iran, 2007–2019. Front Pediatr. 2022;10:988371.PubMedCrossRef
43.
Holman RC, et al. Racial/ethnic differences in the incidence of Kawasaki syndrome among children in Hawaii. Hawaii Med J. 2010;69(8):194–7.PubMedPubMedCentral
44.
45.
46.
Lee J, Lee YJ, Kim Y. A high prevalence of prediabetes and vitamin D deficiency are more closely associated in women: results of a cross-sectional study. J Int Med Res. 2021;49(7):3000605211033384.PubMedCrossRef
47.
Varghese SB, Benoit J, McIntyre T. Vitamin D Levels in Ethnic Minority Adolescents in Primary Care. J Pediatr Health Care. 2022;36(5):443–8.PubMedCrossRef
48.
Yin X, et al. Association between vitamin D serum levels and insulin resistance assessed by HOMA-IR among non-diabetic adults in the United States: results from NHANES 2007–2014. Front Nutr. 2022;9:883904.PubMedPubMedCentralCrossRef
49.
50.
Smolders J, et al. Letter to the Editor: Vitamin D deficiency in COVID-19: mixing up cause and consequence. Metabolism. 2021;115:154434.PubMedCrossRef
51.
52.
53.
Wang L, et al. Kawasaki disease- management strategies given symptoms overlap to COVID-19: a review. JNMA J Nepal Med Assoc. 2021;59(236):417–24.PubMedPubMedCentral
54.
Men Q-X, Li X-M, Zhao N. Influencing factos of coronary artery disease in children with Kawasaki disease. Clin Med. 2022;42(7):3.
55.
Stounbjerg NG, et al. Vitamin D status of 3-year-old children in Denmark: determinants and associations with bone mineralisation and blood lipids. Eur J Nutr. 2023;62(3):1441–51.PubMedCrossRef
56.
Makino N, et al. Descriptive epidemiology of Kawasaki disease in Japan, 2011–2012: from the results of the 22nd nationwide survey. J Epidemiol. 2015;25(3):239–45.PubMedCrossRef
Metadata
Title
The effect of vitamin D status on the occurrence of Kawasaki Disease: a meta-analysis
Authors
Haixiang Zhang
Fuyong Jiao
Jiaojiao Wang
Cuixiang Xu
Kejin Zhang
Publication date
01-12-2024
Publisher
BioMed Central
Published in
BMC Pediatrics / Issue 1/2024
Electronic ISSN: 1471-2431
DOI
https://doi.org/10.1186/s12887-024-04768-1

Other articles of this Issue 1/2024

BMC Pediatrics 1/2024 Go to the issue

Research

Clinical features of intussusception in children secondary to small bowel tumours: a retrospective study of 31 cases

Research

Spatial disparity and associated factors of diarrhea among under-five children in Rwanda: a multilevel logistic regression analysis

Research

Emotional and behavioural difficulties among children and adolescents attending “ART teen clubs” in Mzuzu City in northern Malawi: a cross-sectional study

Research

Efficacy of atypical antipsychotics in the treatment of fecal incontinence in children and adolescents: a randomized clinical trial

Research

Survival status and its predictors among undernourished children on antiretroviral therapy in Bahir Dar city, Northwest Ethiopia, 2010 – 2020, a multicenter retrospective cohort study

Research

Health seeking behaviour and knowledge on neonatal danger signs among neonatal caregivers in Upper Denkyira East Municipality, Ghana